Sox2 is involved in paclitaxel resistance of the prostate cancer cell line PC-3 via the PI3K/Akt pathway

Molecular Medicine Reports

Volumn 10, Issue 6, 2014, Pages 3169-3176

  Li, Dong ^a   Zhao, Li Nan ^a   Zheng, Xiu Lan ^a   Lin, Ping ^a   Lin, Feng ^a   Li, Yue ^a   Zou, Hai Feng ^a   Cui, Rong Jun ^a   Chen, Hui ^a   Yu, Xiao Guang ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Drug resistance; Paclitaxel; Phosphoinositide 3 kinase Akt pathway; Prostate cancer; Sox2

Indexed keywords

BIRC5 PROTEIN, HUMAN; CYCLIN E; INHIBITOR OF APOPTOSIS PROTEIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

APOPTOSIS; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HUMAN; MALE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN E; DRUG RESISTANCE, NEOPLASM; G1 PHASE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; S PHASE; SIGNAL TRANSDUCTION; SOXB1 TRANSCRIPTION FACTORS;

EID: 84914118364     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2630     Document Type: Article

References (44)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Moon C, Park JC, Chae YK, Yun JH and Kim S: Current status of experimental therapeutics for prostate cancer. Cancer Lett 266: 116-134, 2008.
3. Petrylak DP: Docetaxel (Taxotere) in hormone-refractory prostate cancer. Semin Oncol 27: 24-29, 2000.
4. Seruga B, Ocana A and Tannock IF: Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 8: 12-23, 2011.
5. Linn DE, Yang X, Sun F, et al: A Role for OCT4 in Tumor Initiation of Drug-Resistant Prostate Cancer Cells. Genes Cancer 1: 908-916, 2010.
6. Wu K, Xie D, Zou Y, et al: The mechanism of DAB2IP in chemo-resistance of prostate cancer cells. Clin Cancer Res 19: 4740-4749, 2013.
7. Pevny LH and Lovell-Badge R: Sox genes find their feet. Curr Opin Genet Dev 7: 338-344, 1997.
8. Wegner M: From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res 27: 1409-1420, 1999.
9. Kamachi Y, Uchikawa M and Kondoh H: Pairing SOX off: with partners in the regulation of embryonic development. Trends Genet 16: 182-187, 2000.
10. Masui S, Nakatake Y, Toyooka Y, et al: Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol 9: 625-635, 2007.
11. Fong H, Hohenstein KA and Donovan PJ: Regulation of self-renewal and pluripotency by Sox2 in human embryonic stem cells. Stem Cells 26: 1931-1938, 2008.
12. Takahashi K, Tanabe K, Ohnuki M, et al: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872, 2007.
13. Takahashi K and Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676, 2006.
14. Yamanaka S: Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 1: 39-49, 2007.
15. Ben-Porath I, Thomson MW, Carey VJ, et al: An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507, 2008.
16. Gangemi RM, Griffero F, Marubbi D, et al: Sox2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 27: 40-48, 2009.
17. Bass AJ, Watanabe H, Mermel CH, et al: Sox2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41: 1238-1242, 2009.
18. Güre AO, Stockert E, Scanlan MJ, et al: Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc Natl Acad Sci USA 97: 4198-4203, 2000.
19. Hussenet T, Dali S, Exinger J, et al: SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One 5: e8960, 2010.
20. Ye F, Li Y, Hu Y, Zhou C, Hu Y and Chen H: Expression of Sox2 in human ovarian epithelial carcinoma. J Cancer Res Clin Oncol 137: 131-137, 2011.
21. Jia X, Li X, Xu Y, et al: SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J Mol Cell Biol 3: 230-238, 2011.
22. Saigusa S, Tanaka K, Toiyama Y, et al: Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 16: 3488-3498, 2009.
23. Rao GH, Liu HM, Li BW, et al: Establishment of a human colorectal cancer cell line P6C with stem cell properties and resistance to chemotherapeutic drugs. Acta Pharmacol Sin 34: 793-804, 2013.
24. Tian T, Zhang Y, Wang S, Zhou J and Xu S: Sox2 enhances the tumorigenicity and chemoresistance of cancer stem-like cells derived from gastric cancer. J Biomed Res 26: 336-345, 2012.
25. Gen Y, Yasui K, Nishikawa T and Yoshikawa T: SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway. Cancer Sci 104: 810-816, 2013.
26. Kregel S, Kiriluk KJ, Rosen AM, et al: Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS One 8: e53701, 2013.
27. Kim SH, Juhnn YS and Song YS: Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann N Y Acad Sci 1095: 82-89, 2007.
28. Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE and Tsang BK: Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol 1: 66, 2003.
29. Smith DA, Kiba A, Zong Y and Witte ON: Interleukin-6 and oncostatin-M synergize with the PI3K/AKT pathway to promote aggressive prostate malignancy in mouse and human tissues. Mol Cancer Res 11: 1159-1165, 2013.
30. Barile E, De SK, Feng Y, et al: Synthesis and SAR studies of dual AKT/NF-kappaB inhibitors against melanoma. Chem Biol Drug Des 82: 520-533, 2013.
31. Hu L, Hofmann J, Lu Y, Mills GB and Jaffe RB: Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62: 1087-1092, 2002.
32. Alimonti A, Carracedo A, Clohessy JG, et al: Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 42: 454-458, 2010.
33. Trotman LC, Niki M, Dotan ZA, et al: Pten dose dictates cancer progression in the prostate. PLoS Biol 1: E59, 2003.
34. Makhov PB, Golovine K, Kutikov A, et al: Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther 11: 1510-1517, 2012.
35. Franken NA, Rodermond HM, Stap J, Haveman J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc 1: 2315-2319, 2006.
36. Huang CC, Aronstam RS, Chen DR and Huang YW: Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles. Toxicol In Vitro 24: 45-55, 2010.
37. Jiang S, Zu Y, Fu Y, Zhang Y and Efferth T: Activation of the mitochondria-driven pathway of apoptosis in human PC-3 prostate cancer cells by a novel hydrophilic paclitaxel derivative, 7-xylosyl-10-deacetylpaclitaxel. Int J Oncol 33: 103-111, 2008.
38. Lin F, Lin P, Zhao D, et al: Sox2 targets cyclinE, p27 and survivin to regulate androgen-independent human prostate cancer cell proliferation and apoptosis. Cell Prolif 45: 207-216, 2012.
39. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550, 2006.
40. Yang YI, Lee KT, Park HJ, et al: Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway. Carcinogenesis 33: 2488-2498, 2012.
41. Bae KM, Su Z, Frye C, et al: Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J Urol 183: 2045-2053, 2010.
42. Sherr CJ: G1 phase progression: cycling on cue. Cell 79: 551-555, 1994.
43. Altieri DC and Marchisio PC: Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 79: 1327-1333, 1999.
44. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M and Yang L: Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 281: 25903-25914, 2006.